Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review

Table 3 Cerebral perfusion measurement

Reference	Triple-H components	Prophylactic/Therapeutic	CBF Technique	Measuring location	Timing after Intervention
Ekelund, 2002 [18]	isovolemic hemodilution or hypervolemic hemodilution	Therapeutic	¹³³Xe SPECT	Whole brain	< 24 hours
Mori, 1995 [14]	hypervolemic hemodilution	Therapeutic	¹²³I-IMP e.s.c.	Ipsilateral to craniotomy	5 to 7 days
Yamakami, 1987 [21]	hypervolemia	Prophylactic	¹³³Xe e.s.c.	Ipsilateral to craniotomy	< 24 hours
Lennihan, 2000 [13]	hypervolemia	Prophylactic	¹³³Xe e.s.c.	Whole brain	< 24 hours 5 to 7 days 12 to 14 days
Tseng, 2003 [23]	hypervolemia	Therapeutic	XeCT	Whole brain	< 24 hours
Jost, 2005 [22]	hypervolemia	Therapeutic	PET	Whole brain	< 24 hours
Muizelaar, 1986 [25]	hypertension	Therapeutic	¹³³Xe e.s.c.	Whole brain	< 24 hours
Touho, 1992 [20]	hypertension	Both	XeCT	Ipsilateral to craniotomy	< 24 hours
Darby, 1994 [24]	hypertension	Therapeutic	XeCT	Whole brain	< 24 hours
Origitano, 1990 [15]	Triple-H	Prophylactic	¹³³Xe e.s.c.	Whole brain	< 24 hours
Muench, 2007 [19]	Triple-H or hypertension or hypervolemic hemodilution	Prophylactic	thermal diffusion microprobe	in flow territory distal to aneurysm	< 24 hours

ISSN: 1364-8535